2016
DOI: 10.1111/liv.13253
|View full text |Cite
|
Sign up to set email alerts
|

Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Abstract: Four-year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

11
164
4
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 193 publications
(180 citation statements)
references
References 31 publications
11
164
4
1
Order By: Relevance
“…43 The most likely explanation for these findings is the presence of concomitant liver injury such as alcoholic or non-alcoholic fatty liver disease. 34,44 In contrast, transient ALT flares may indicate some level of immune reconstitution and can be associated with favourable outcomes. 1,45,46 The loss of HBsAg is regarded as the optimal treatment endpoint, termed 'functional cure', but it is only rarely achieved with our current antiviral armamentarium.…”
Section: Recommendationsmentioning
confidence: 99%
See 3 more Smart Citations
“…43 The most likely explanation for these findings is the presence of concomitant liver injury such as alcoholic or non-alcoholic fatty liver disease. 34,44 In contrast, transient ALT flares may indicate some level of immune reconstitution and can be associated with favourable outcomes. 1,45,46 The loss of HBsAg is regarded as the optimal treatment endpoint, termed 'functional cure', but it is only rarely achieved with our current antiviral armamentarium.…”
Section: Recommendationsmentioning
confidence: 99%
“…It therefore represents the cornerstone endpoint of all our current therapeutic attempts. 1,25,[34][35][36][37][38][39][40] The level of HBV DNA suppression that should be attained in order to achieve these benefits is not well defined, but inferred that the lower, the better. Treatment-induced HBeAg loss and seroconversion to antiHBe characterises the induction of a partial immune control often leading to a low replicative phase of the chronic HBV infection.…”
Section: Recommendationsmentioning
confidence: 99%
See 2 more Smart Citations
“…Several large population-based and international studies have reveal that antiviral therapy could reduce the incidence of hepatic failure, cirrhosis, HCC, and mortality in CHB patients without alcoholism [33][34][35][36][37][38][39][40].…”
Section: Treatment In Patients With Concomitant Hbv Infection and Alcmentioning
confidence: 99%